Receptor Life Sciences has raised $29 million for development of several cannabinoid products, the company said. In 2016, MannKind Corporation announced that it had licensed its dry powder inhalation technology to Receptor, which was then newly formed. According to the company, "Receptor’s inhalation technology combines a simple-to-use, breath-powered inhaler … [Read more...] about Receptor Life Sciences raises $29 million
News
Copley Scientific officially opens expanded headquarters
Inhaler testing equipment company Copley Scientific has announced the official opening of its newly expanded headquarters in Nottingham, UK. The company announced the project, which nearly doubled the size of the existing building, in February 2017. The headquarters now includes increased space for product development, manufacturing, offices, and training. Copley … [Read more...] about Copley Scientific officially opens expanded headquarters
Glenmark opens new manufacturing facility in US
Glenmark Pharmaceuticals has officially opened its first US manufacturing site in Monroe, North Carolina, the company said. The 100,000 sq ft, $100 million facility will eventually produce hundreds of millions of doses in various forms annually, including 25-30 million inhalation ampoules. The site currently employs 168 people, and the Glenmark said that it expects … [Read more...] about Glenmark opens new manufacturing facility in US
Philips launches InnoSpire Go nebulizer in US
Royal Philips has announced the launch of the InnoSpire Go hand-held vibrating mesh nebulizer system in the US. InnoSpire Go is already available in the UK, Australia, Denmark, Finland, Germany, and Norway. Philips acquired the vibrating mesh nebulizer technology from Aerogen in 2014. According to the company, InnoSpire Go delivers 2.5 ml of albuterol … [Read more...] about Philips launches InnoSpire Go nebulizer in US
Nevan Charles Elam joins board of Softhale
Belgian soft mist inhaler company Softhale has announced the appointment of Nevan Charles Elam to its board of directors. Currently Chairman and CEO of Rezolute, Elam was formerly Senior VP and Head of the Pulmonary Business Unit at Nektar Therapeutics. He has served on the boards of Nektar spin-out Pearl Therapeutics and Aerogen, and currently serves on the board of … [Read more...] about Nevan Charles Elam joins board of Softhale
GSK opens new Ellipta API manufacturing facility in Scotland
According to the Scottish government, a new manufacturing facility built by GSK in Montrose to produce APIs for its Ellipta dry powder inhalers officially opened on October 22, 2018, with Scottish First Minister Nicola Sturgeon in attendance. Sturgeon commented, “This new facility is testament to GSK’s commitment to Montrose and reinforces the region’s position … [Read more...] about GSK opens new Ellipta API manufacturing facility in Scotland
David Harris joins Cambridge Design Partnership
Cambridge Design Partnership (CDP) has announced the appointment of OINDP device designer David Harris to head up the company's respiratory drug delivery development business. According to CDP, the company is entering "a new phase of growth in the sector." Harris was previously Head of Respiratory Drug Delivery at PA Consulting and at Team Consulting and also … [Read more...] about David Harris joins Cambridge Design Partnership
Adapt and Opiant file suit in response to Perrigo ANDA for naloxone nasal spray
Perrigo said that Adapt Pharma and Opiant Pharmaceuticals have initiated patent litigation in the United States District Court for the District of New Jersey in regards to Perrigo's recently filed ANDA for a generic version of Narcan naloxone nasal spray for the treatment of opioid overdose. Adapt Pharma licensed naloxone nasal spray from Opiant (then called … [Read more...] about Adapt and Opiant file suit in response to Perrigo ANDA for naloxone nasal spray
Galecto Biotech raises €79 million for Phase 2/3 study of its inhaled galectin-3 inhibitor
Galecto Biotech announced that it raised €79 million in a series C financing round that will be used to fund a Phase 2/3 study of its TD139, an inhaled galectin-3 inhibitor, for the treatment of idiopathic pulmonary fibrosis (IPF). New investors included Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Maverick Ventures, Seventure Partners, and … [Read more...] about Galecto Biotech raises €79 million for Phase 2/3 study of its inhaled galectin-3 inhibitor
VistaGen acquires second Pherin nasal spray
VistaGen Therapeutics said that it has exercised an option to acquire an exclusive worldwide license for Pherin Pharmaceutical's PH10 intranasal steroid, which is in Phase 2 development for the treatment of major depressive disorder (MDD). According to the company, a Phase 2a study of PH10 conducted by MIchael Liebowitz of Columbia University demonstrated significant … [Read more...] about VistaGen acquires second Pherin nasal spray